Journal of Clinical Medicine (May 2023)

Prognostic Role of Polyvascular Involvement in Patients with Symptomatic Peripheral Artery Disease

  • Luise Adam,
  • Eva Strickler,
  • Meisam K. Borozadi,
  • Simone Bein,
  • Arjola Bano,
  • Taulant Muka,
  • Heinz Drexel,
  • Jörn F. Dopheide

DOI
https://doi.org/10.3390/jcm12103410
Journal volume & issue
Vol. 12, no. 10
p. 3410

Abstract

Read online

Background: Statin therapy is recommended for patients with peripheral artery disease (PAD). However, PAD patients with polyvascular (PV) extent remain threatened by an increased residual cardiovascular (CV) risk. Purpose: To investigate the association of prescribed statin therapy and mortality in PAD patients with or without PV extent. Methods: A single-center retrospective longitudinal observational study originating from a consecutive registry with 1380 symptomatic PAD patients over a mean observational time of 60 ± 32 months. The association of atherosclerotic extent and statin use (PAD, plus one additional region (CAD or CeVD, [+1 V]), +2 vascular regions (+CAD and CeVD [+2 V]) with the risk of all-cause mortality was evaluated using Cox proportional hazard models adjusted for potential confounding factors. Results: The mean age of the study’s participants was 72.0 ± 11.7 years, with 36% being female. PAD patients with PV extent [+1 V] and [+2 V] were older and suffered from diabetes, hypertension, or dyslipidemia more often; they, too, had more severely impaired kidney function (all p p p Conclusion: PV patients receive better statin therapy than PAD-only patients but nevertheless still have higher mortality rates. Future studies are needed to explore whether more aggressive LDL-lowering treatment for PAD patients may be translated into better prognosis.

Keywords